Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exilam Plus 10 is a combination pharmaceutical product marketed by ADN Life Sciences, primarily indicated for the management of anxiety disorders, particularly when associated with comorbid depression. It contains two active ingredients: escitalopram, a selective serotonin reuptake inhibitor (SSRI), and etizolam, a thienodiazepine. Escitalopram works by increasing the levels of serotonin in the synaptic cleft by inhibiting its reuptake into the presynaptic neuron, thereby improving mood and reducing anxiety symptoms. Etizolam acts as a potent anxiolytic by binding to the benzodiazepine site of the GABA-A receptor, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) throughout the central nervous system. This combination provides both long-term stabilization of mood and rapid relief from acute anxiety symptoms. It is typically administered orally in tablet form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + etizolam.